Inhibrx Biosciences, Inc. (INBX)
| Market Cap | 166.04M |
| Revenue (ttm) | 200,000 |
| Net Income (ttm) | 1.69B |
| Shares Out | 14.48M |
| EPS (ttm) | 112.62 |
| PE Ratio | 0.10 |
| Forward PE | n/a |
| Dividend | $0.85 (7.40%) |
| Ex-Dividend Date | May 30, 2024 |
| Volume | 84,648 |
| Open | 11.33 |
| Previous Close | 11.47 |
| Day's Range | 11.33 - 11.48 |
| 52-Week Range | 10.80 - 18.95 |
| Beta | 2.88 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 8, 2025 |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-sma... [Read more]
Financial Performance
Financial StatementsNews
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage developm...
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncol...
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announc...
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following th...
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p...
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong em...
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials an...
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeu...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved th...
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% ...
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (N...
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously ...
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeli...
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to tr...
Sanofi to Buy Rare-Disease Assets From Inhibrx
Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.
France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln
French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi's portfolio growth strategy and complement...
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 ass...
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipel...
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today ann...
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an...
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announc...